Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Singapore Gains Momentum As Major R&D, Manufacturing Hub; Sees Double-digit Pharma Sector Growth

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Output of Singapore's biomedical manufacturing cluster increased 14.8 percent last year, according to Singapore's Economic Development Board. Within the cluster, the pharmaceuticals segment grew 15.6 percent with higher levels of production of active pharmaceutical ingredients. Output of the medical technology segment edged up 0.8 percent to meet export orders for surgical and medical instruments

You may also be interested in...



Deals of the Week: Ante Up For Antisense, Pharma Places Another Isis Bet

The biotech brings Roche on as its seventh biopharma partner, building on the more than $5 billion in potential partnership revenue the biotech had already amassed. If all goes as planned, Isis will add five marketed products within the next five years to the newly approved Kynamro. But Wall Street doesn’t expect Isis’ revenues to increase much anytime soon. Plus more notable deals this week…

GSK Says "Unique" Collaboration With Singapore Academics Aimed Squarely At Drug Discovery

SINGAPORE - GlaxoSmithKline said four new drug research collaborations between Singapore-based academics and GSK's global drug discovery network are "unique" alliances for the firm, pairing seasoned researchers from GSK's global network with promising academic work to bring new drugs to the market

GSK Says "Unique" Collaboration With Singapore Academics Aimed Squarely At Drug Discovery

SINGAPORE - GlaxoSmithKline said four new drug research collaborations between Singapore-based academics and GSK's global drug discovery network are "unique" alliances for the firm, pairing seasoned researchers from GSK's global network with promising academic work to bring new drugs to the market

Related Content

UsernamePublicRestriction

Register

SC074751

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel